BRAF and cutaneous melanoma: Despite this low expression, we showed that RC48 exhibited superior therapeutic efficacy by inducing cell cycle arrest, apoptosis, and inhibiting of cell motility in HER2-positive and BRAF-mutant cutaneous melanoma cells.